Enasidenib Mesylate

Enasidenib Mesylate (CAS No.: 1650550-25-6) is a synthetic small molecule classified by mechanism of action as a selective inhibitor of mutant isocitrate dehydrogenase 2 (IDH2), and is commonly used as a chemical probe in biomedical research on cancer metabolism, epigenetic regulation, and myeloid cell differentiation; by specifically targeting neomorphic IDH2 variants (such as R140Q and R172K), it inhibits the aberrant production of 2?hydroxyglutarate, thereby alleviating downstream interference with the α?ketoglutarate-dependent dioxygenase family, and promotes myeloid lineage-associated maturation programs under experimental conditions; in biochemical and cellular systems, it generally shows high selectivity for mutant IDH2 over wild-type IDH2, with activity levels often observed in the nanomolar range in enzymatic assays and in the nanomolar to low micromolar range in cell models, consistent with reduced intracellular 2?hydroxyglutarate and upregulation of differentiation markers; its research applications include target validation in IDH2-mutant leukemia models, analysis of metabolic and epigenomic pathways, use as a reference control in phenotype- or target-oriented screening workflows, and investigation of metabolic reprogramming and lineage outcomes in animal models carrying IDH2 mutations; the treatment duration, concentration, or dose used in specific experiments should be optimized according to system parameters and research objectives, and all applications are strictly limited to laboratory research settings, with no human ingestion or any clinical use involved.